BODE Index — COPD Prognosis
mMRC dyspnoea grade (0 = no breathlessness, 4 = too breathless to leave home)
详细指南即将推出
我们正在为BODE Index (COPD)编写全面的教育指南。请尽快回来查看逐步解释、公式、真实案例和专家提示。
The BODE Index is a multidimensional grading system for COPD that was developed by Celli and colleagues in 2004 to better predict all-cause and respiratory mortality than FEV1 alone. Its acronym stands for Body mass index (B), Obstruction as measured by FEV1 percent predicted (O), Dyspnoea using the Modified Medical Research Council (mMRC) scale (D), and Exercise capacity using the 6-minute walk test distance (E). Each domain is scored from 0 to 3 (except BMI, which is 0 or 1), yielding a total BODE score of 0 to 10. Higher scores indicate worse prognosis. A landmark study in the New England Journal of Medicine demonstrated that the BODE Index was significantly better at predicting all-cause mortality and respiratory-related mortality than FEV1 alone, with each 1-point increase in BODE score associated with a 34% increase in the risk of death from any cause. The index integrates the systemic manifestations of COPD — including weight loss and muscle wasting (low BMI) and functional limitation (poor 6MWT performance) — that are not captured by spirometry alone. This reflects the current understanding of COPD as a complex systemic disease rather than purely a lung condition. In practice, BODE scores of 5–6 or higher are generally used as a clinical threshold for considering lung transplant evaluation referral, as these patients have a 50% or greater mortality over 4 years. BODE Index assessment requires spirometry (post-bronchodilator FEV1% predicted), mMRC dyspnoea grade, 6-minute walk test (performed in a standardised 30-metre corridor), and BMI (calculated from weight and height).
BODE Score = BMI score + Obstruction score + Dyspnoea score + Exercise score BMI: >21 = 0 points; ≤21 = 1 point FEV1% predicted: ≥65% = 0 points 50–64% = 1 point 36–49% = 2 points ≤35% = 3 points mMRC Dyspnoea: 0–1 = 0 points 2 = 1 point 3 = 2 points 4 = 3 points 6MWT (metres): ≥350 m = 0 points 250–349 m = 1 point 150–249 m = 2 points ≤149 m = 3 points Total score 0–10; higher = worse prognosis; ≥5 = lung transplant referral threshold
- 1Measure patient's weight (kg) and height (m); calculate BMI = kg/m². Score BMI: >21 = 0 points; ≤21 = 1 point.
- 2Record post-bronchodilator FEV1% predicted from spirometry. Score as: ≥65% = 0; 50–64% = 1; 36–49% = 2; ≤35% = 3.
- 3Assess mMRC dyspnoea score: 0 = no breathlessness except strenuous exercise; 1 = hurrying on level ground; 2 = slower than peers on level ground; 3 = stopping for breath after 100 m; 4 = too breathless to leave house or dress.
- 4Perform standardised 6-minute walk test (6MWT) in a flat 30-metre corridor; record maximum distance in metres. Score as: ≥350 m = 0; 250–349 m = 1; 150–249 m = 2; ≤149 m = 3.
- 5Sum all four domain scores to calculate the BODE Index (0–10).
- 6Interpret: BODE 0–2 = low risk; BODE 3–4 = moderate; BODE 5–6 = high (4-year mortality ~40%); BODE 7–10 = very high (4-year mortality >80%).
- 7Consider lung transplant referral for BODE score ≥5, particularly in patients <65 years with rapidly progressive disease.
BODE 0 — excellent prognosis; continue standard COPD management
All four domains score zero, indicating good functional reserve, preserved exercise capacity, minimal dyspnoea, and adequate nutritional status. The 4-year mortality rate in this BODE category is below 15%. Standard LAMA/LABA bronchodilator therapy and smoking cessation are the priorities.
BODE 4 — moderate prognosis; 4-year mortality ~30%; intensify COPD therapy, consider pulmonary rehabilitation
The low BMI (≤21) scores a point, reflecting cachexia common in moderate-to-severe COPD. Moderate obstruction, dyspnoea interfering with activity, and reduced 6MWT distance each contribute one point. Pulmonary rehabilitation significantly improves 6MWT distance and dyspnoea score, potentially lowering the BODE score.
BODE 8 — very high risk; 4-year mortality >80%; urgent lung transplant referral
A BODE of 8 places this patient in the highest-mortality COPD category. Very severe obstruction (FEV1 28%), significant cachexia, and severe functional limitation indicate advanced systemic disease. This patient should be urgently evaluated for bilateral lung transplantation if otherwise eligible (typically age <65, no major comorbidities).
BODE 6 — high risk; mMRC-4 severely limits function; lung transplant referral appropriate
Moderate FEV1 impairment alone would suggest a lower BODE score, but the patient's symptom burden (mMRC 4 — unable to leave house due to breathlessness) and poor exercise capacity drive the score to 6. This illustrates the advantage of BODE over FEV1 alone: the full disease burden is captured regardless of how 'mild' the spirometry appears.
Prognosis communication at COPD diagnosis — explaining likely disease trajectory to patients and families based on BODE score, enabling practitioners to make well-informed quantitative decisions based on validated computational methods and industry-standard approaches
Lung transplant referral timing — BODE ≥5 triggers evaluation at specialist transplant centres, helping analysts produce accurate results that support strategic planning, resource allocation, and performance benchmarking across organizations, where accurate numerical computation is essential for producing reliable outputs that inform planning, evaluation, and continuous improvement processes in both corporate and individual settings
Pulmonary rehabilitation programme outcome measurement — pre- and post-PR BODE scores quantify the functional benefit achieved, allowing professionals to quantify outcomes systematically and compare scenarios using reliable mathematical frameworks and established formulas
Clinical trial stratification — BODE score is used to match treatment and control groups in COPD intervention trials, supporting data-driven evaluation processes where numerical precision is essential for compliance, reporting, and optimization objectives
Palliative care integration — very high BODE scores (7–10) prompt advance care planning and palliative care referral discussions, which requires precise quantitative analysis to support evidence-based decisions, strategic resource allocation, and performance optimization across diverse organizational contexts and professional disciplines
Patients Unable to Complete 6MWT
Severe arthritis, musculoskeletal disease, peripheral vascular disease, or severe cardiac dysfunction may prevent completion of the 6MWT. In these cases, the BODEx modification (using exacerbation frequency) can be used as a surrogate. Alternatively, the incremental shuttle walk test is conducted on a fixed course and may be more feasible in some patients.
COPD with Obesity Hypoventilation
Morbidly obese patients with COPD and obesity hypoventilation syndrome often have high BMI (scoring 0 on the BODE BMI domain) despite severe functional limitation. This can underestimate their mortality risk. The BMI domain of BODE was designed to capture cachexia (common in classic COPD) rather than obesity — interpretation requires clinical judgement in this subgroup.
Alpha-1 Antitrypsin Deficiency COPD
Patients with alpha-1 antitrypsin deficiency develop emphysema at a younger age (often in their 30s–40s) and may have BODE scores warranting transplant evaluation while still relatively young. These patients should be referred to specialised centres experienced in both alpha-1 antitrypsin augmentation therapy and lung transplantation.
Post-LVRS (Lung Volume Reduction Surgery)
Lung volume reduction surgery (LVRS) improves FEV1, reduces hyperinflation, and improves exercise capacity in selected upper-lobe-predominant emphysema patients. BODE score typically improves significantly post-LVRS, and improved BODE score predicts sustained post-operative survival benefit. BODE is used to monitor outcomes after LVRS.
| BODE Score | Approximate 4-Year Mortality | Action |
|---|---|---|
| 0–2 | ~15% | Standard COPD management; smoking cessation |
| 3–4 | ~30% | Intensify therapy; pulmonary rehabilitation; annual reassessment |
| 5–6 | ~40% | Lung transplant evaluation; maximise medical therapy |
| 7–10 | >80% | Urgent transplant listing if eligible; palliative care planning |
Why is BODE superior to FEV1 alone for prognosis?
FEV1 measures only one dimension of COPD — airflow limitation. COPD is a systemic disease with extrapulmonary manifestations including skeletal muscle wasting, nutritional depletion, cardiovascular disease, and depression. These systemic effects significantly influence mortality and quality of life. BODE captures these dimensions through BMI (nutritional status), dyspnoea (symptom burden), and 6MWT (exercise capacity), providing a far more complete prognostic picture.
How is the 6-minute walk test standardised?
The 6MWT is performed in a flat corridor of at least 30 metres. The patient walks at their own maximum pace for 6 minutes, turning at each end. Oxygen saturation, heart rate, and dyspnoea are monitored. Rest is permitted but the clock continues. The total distance walked is recorded. Standardised encouragement phrases are given at one-minute intervals. Two tests are performed and the best result is used.
What is the mMRC dyspnoea scale?
The mMRC (Modified Medical Research Council) dyspnoea scale grades breathlessness from 0 to 4: Grade 0 = breathless only with strenuous exercise; Grade 1 = short of breath when hurrying or walking up a slight hill; Grade 2 = walks slower than people of the same age due to breathlessness, or has to stop for breath when walking at own pace; Grade 3 = stops for breath after walking 100 metres or after a few minutes on level ground; Grade 4 = too breathless to leave the house or breathless when dressing.
Can pulmonary rehabilitation change the BODE score?
Yes. Pulmonary rehabilitation consistently improves two of the four BODE domains: 6MWT distance (exercise capacity) and mMRC dyspnoea score. This can reduce the BODE score by 1–2 points. Studies suggest a BODE reduction of ≥1 point is associated with improved survival in COPD. This is one of the strongest arguments for offering pulmonary rehabilitation to all symptomatic COPD patients.
Is BODE Index valid for all COPD patients?
The BODE Index was derived and validated in stable, ambulatory COPD patients. It may be less reliable during acute exacerbations (when functional capacity is transiently reduced), in COPD complicated by major musculoskeletal disease preventing 6MWT completion, or in very mild COPD (GOLD 1) where all scores may be zero. It should not be applied to non-COPD respiratory diseases.
What is the updated BODEx or i-BODE index?
Modifications of BODE have been proposed. The BODEx index replaces the 6MWT with exacerbation history (frequency in the previous year), which is easier to collect in routine practice without a supervised walk test. The i-BODE index incorporates incremental shuttle walk test distance. However, the original BODE with 6MWT remains the most validated and widely referenced version.
What BODE score qualifies for lung transplant evaluation?
ISHLT (International Society for Heart and Lung Transplantation) guidelines recommend listing COPD patients for lung transplant when BODE ≥7, or BODE 5–6 with rapid decline, significant hypercapnia (PaCO2 >50 mmHg), pulmonary hypertension, or frequent exacerbations. BODE ≥5 at baseline is used by many centres as a threshold for starting the transplant evaluation process.
How does BODE compare to GOLD ABCD assessment?
The GOLD ABCD tool categorises patients into groups A, B, C, D based on symptom burden (CAT score or mMRC) and exacerbation history. It guides pharmacological treatment selection. BODE is a prognostic tool for mortality prediction rather than a treatment guide. Both tools use symptoms and functional data but serve different clinical purposes; they complement each other in comprehensive COPD management.
专业提示
Consider pulmonary rehabilitation for every COPD patient with a BODE score of 2 or higher — not just for those with very high scores. Even modest improvements in 6MWT (≥50 m) and dyspnoea (one mMRC grade) can reduce the BODE score by 1–2 points, which translates into meaningful mortality reduction. Pulmonary rehabilitation is one of the most cost-effective interventions in COPD management.
你知道吗？
The BODE Index was not conceived at a respiratory conference but during a late-night conversation between Bartolomé Celli and colleagues who were frustrated that lung function tests did not explain why some COPD patients thrived while others rapidly declined. The acronym BODE (Spanish slang meaning 'goat smell' in some Latin American countries) was deliberately chosen to be memorable — and it worked: the 2004 NEJM paper became one of the most-cited pulmonology articles of the 21st century.
参考资料
- ›Celli BR et al. The Body-Mass Index, Airflow Obstruction, Dyspnea, and Exercise Capacity Index in Chronic Obstructive Pulmonary Disease. N Engl J Med. 2004;350(10):1005-1012.
- ›Global Initiative for Chronic Obstructive Lung Disease (GOLD). Global Strategy for COPD 2024.
- ›Spruit MA et al. An official ATS/ERS statement: key concepts and advances in pulmonary rehabilitation. Am J Respir Crit Care Med. 2013;188(8):e13-64.
- ›Oga T et al. Analysis of the factors related to mortality in chronic obstructive pulmonary disease: role of exercise capacity and health status. Am J Respir Crit Care Med. 2003;167(4):544-549.